After a moderate growth in revenue for the month of May, the Indian pharma market witnessed a healthy growth in its revenue for the month of June. The revenue has grown around 8.8% YoY basis while in May it grew only 5.2% compared to the corresponding month in the previous year.
According to AIOCD-AWACS, the Indian pharmaceuticals market’s revenue for the first six months of 2024 that is from January to June, grew at an average rate of 8.5% YoY however, the growth in the volume was at negative 0.3% YoY basis.
Double Digit Growth
The revenue surge in June has been mainly driven by double-digit growth in revenue generated from anti-infective medicines whose demand surged owing to the seasonal change and infections during this time. Then cardiac medicines also were high on demand followed by gastro and respiratory medicines. These four segments of pharma drugs witnessed the highest growth in their revenue in the last month.
The overall pharma market growth in June was also driven by new launches and the price of the medicines. Prices grew by 6% in June 2024 compared to 5% in June 2023. In addition, new launches of medicines increased by 2.6% in the month of June while it was 3.1% in June 2023. The volume growth was around 0.2% in the month of June compared to negative 2.1% in June 2023.
Segment-wise Growth in June 2024
The top segments within the pharma industry, which drove the Indian pharma market revenue growth in June include Cardiac medicines, which held a market share of around 13.2%. The MAT or moving annual total growth was 9% for this segment.
Then there were anti-infective medicines with a MAT growth of 8.7% and a market share of around 12.7%, right after the cardiac medicines.
In third place, was gastro medicines, which held a market share of 11.7%, and its MAT growth was recorded at 8.4% in the month of June.
| Segment | MAT Growth (%) | Market Share in June (%) |
| Cardiac | 9 | 13.2 |
| Anti-infective | 8.7 | 12.7 |
| Gastro | 8.4 | 11.7 |
| Anti-diabetic | 6.7 | 9 |
| Vitamins | 4.6 | 8.6 |
| Respiratory | 5.4 | 8.1 |
| Pain | 7.2 | 7 |
| Derma | 7.5 | 6.7 |
| Neuro/CNS | 8.4 | 6.2 |
| Gynaec | 4.1 | 3.2 |
Source: AIOCD
Pharma Companies performance
If we look at the companies in the pharma industry that drove the Indian pharma growth in the month of June, then it had to be FDC whose revenue grew at 22.2%, outperforming the industry average. Cipla and Glenmark, surging at 16.5% and 16.4% respectively, followed it. With a 15.3%, growth Alkem Laboratories also outgrew the market and in fifth place, Torrent Pharma followed with a 13.6% growth.
GlaxoSmithKline Pharmaceuticals, Sun Pharma, Mankind Pharma, and Indoco Remedies also witnessed growth within the range of 10% to 13% during the previous month.
On the contrary, Dr. Reddy’s Laboratories revenue grew at 7.8%, lower than the industry’s growth, and Ajanta Pharma and Abbott India grew at 7.6% and 6.5%, lower than the industry’s overall growth rate.
Zydus Lifesciences grew the least at 1.2% amongst these pharma giants, while Sanofi India registered a negative growth of 1.4% in its revenue.
Prospects of the Indian Pharmaceuticals Market
According to experts, the growth of the pharmaceutical industry in India can be around 8% to 9% in this financial year 2025 compared to the FY24’s growth of 6.5%. However, the Indian pharma market growth rate would be slower than FY23’s 9.9% growth rate YoY basis.
Source: https://www.ndtvprofit.com/
______________________________________________________________________________________
Disclaimer: Investments in the securities market are subject to market risks; read all the related documents carefully before investing.